Ertan Elif, Çelen İdil, Gül Cengiz
Department of Ophthalmology, University of Health Sciences, Başakşehir Çam Sakura City Hospital, Istanbul, Turkey.
Int Ophthalmol. 2025 Jun 6;45(1):233. doi: 10.1007/s10792-025-03605-3.
This study aimed to evaluate the incidence of ocular hypertension (OHT) following intravitreal dexamethasone (Ozurdex) implantation and to investigate its association with baseline intraocular pressure (IOP).
This retrospective cohort study included 698 patients (1085 eyes) who received Ozurdex implantation for diabetic macular edema, macular edema secondary to retinal vein occlusion, or other retinal disorders. Only patients with a minimum follow-up duration of six months were included. IOP measurements were recorded at baseline and at week 1, and months 1, 2, 3, and 6 post-injection. These values were compared using either the paired Student's t-test or the Wilcoxon signed-rank test, depending on data distribution. Logistic regression analysis was performed to identify independent risk factors for steroid-induced ocular hypertension (SIOHT).
The incidence of SIOHT was 38% (n = 412 eyes). The mean baseline IOP was 15.73 ± 3.4 mmHg, which peaked at month 1 (17.81 ± 4.0 mmHg, p < 0.001) and month 2 (17.30 ± 4.4 mmHg, p < 0.001), then declined and returned close to baseline by month 6 (15.38 ± 4.1 mmHg, p = 0.258). Multivariate analysis revealed that age (40-50 years, OR 2.95, p = 0.001), male gender (OR 1.82, p = 0.001), and higher baseline IOP (OR 1.09, p = 0.003) were significant independent risk factors. Among SIOHT cases, 72.6% exhibited IOP elevations between 25 and 30 mmHg, 22.6% had levels exceeding 30 mmHg, and 4.8% exceeded 35 mmHg. All patients were initially treated with topical IOP-lowering medications, and only 0.7% required trabeculectomy.
Intravitreal Ozurdex implantation is associated with a significant increase in IOP, necessitating close monitoring. Higher baseline IOP and male gender were identified as major risk factors. While the majority of cases were successfully managed with topical therapy, a small proportion required surgical intervention. Further research is warranted to improve risk stratification and optimize management strategies.
本研究旨在评估玻璃体内注射地塞米松(Ozurdex)植入术后高眼压(OHT)的发生率,并探讨其与基线眼压(IOP)的关系。
这项回顾性队列研究纳入了698例患者(1085只眼),这些患者因糖尿病性黄斑水肿、视网膜静脉阻塞继发的黄斑水肿或其他视网膜疾病接受了Ozurdex植入术。仅纳入随访时间至少为6个月的患者。在基线、注射后第1周、第1、2、3和6个月记录眼压测量值。根据数据分布,使用配对t检验或Wilcoxon符号秩检验对这些值进行比较。进行逻辑回归分析以确定类固醇诱导的高眼压(SIOHT)的独立危险因素。
SIOHT的发生率为38%(n = 412只眼)。平均基线眼压为15.73±3.4 mmHg,在第1个月(17.81±4.0 mmHg,p < 0.001)和第2个月(17.30±4.4 mmHg,p < 0.001)达到峰值,然后下降,到第6个月接近基线(15.38±4.1 mmHg,p = 0.258)。多变量分析显示,年龄(40 - 50岁,OR 2.95,p = 0.001)、男性(OR 1.82,p = 0.001)和较高的基线眼压(OR 1.09,p = 0.003)是显著的独立危险因素。在SIOHT病例中,72.6%的眼压升高在25至30 mmHg之间,22.6%超过30 mmHg,4.8%超过35 mmHg。所有患者最初均接受局部降眼压药物治疗,仅0.7%需要小梁切除术。
玻璃体内注射Ozurdex植入术与眼压显著升高相关,需要密切监测。较高的基线眼压和男性被确定为主要危险因素。虽然大多数病例通过局部治疗成功管理,但一小部分需要手术干预。有必要进行进一步研究以改善风险分层并优化管理策略。